The Potential Impact of RCC Molecular Subtypes on Treatment Outcomes

Host: Jody Takemoto, PhD, MEd Guest: David Braun, MD, PhD A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.